ACELYRIN, INC. Reports Positive 16-week Results from Global Izokibep Trial in Psoriatic Arthritis to be Presented at EULAR 2024

In an announcement dated June 5, 2024, ACELYRIN, INC. (Nasdaq: SLRN) reported promising results from its global Phase 2b/3 clinical trial of izokibep, a novel treatment for psoriatic arthritis (PsA). These findings will be highlighted in an oral presentation at the 2024 European Alliance of Associations for Rheumatology Congress, scheduled from June 12-15 in Vienna, Austria. The presentation will be delivered by Dr. Philip Mease, a prominent figure in rheumatology research.

Izokibep is a small protein therapeutic specifically designed to inhibit IL-17A, a validated target in the treatment of PsA and other immune-related conditions. The clinical trial, identified by the reference number NCT05623345, was a global, multi-center, randomized, double-blind, and placebo-controlled study. It evaluated the safety and effectiveness of izokibep administered subcutaneously at doses of 160 mg every week, 160 mg every two weeks, and 80 mg every four weeks, compared to a placebo. The study enrolled 351 adult patients with active PsA across 71 sites in the United States and Europe.

Psoriatic arthritis is a chronic inflammatory disease that manifests in various ways, including joint inflammation, psoriasis, and enthesitis, which is the painful inflammation of the tissues connecting ligaments and tendons to bones. This condition considerably diminishes the quality of life for sufferers. Approximately 30% of the global population with psoriasis, estimated to be 125 million people, are likely to develop PsA. Despite existing treatments, there remains a significant unmet need for more effective therapies that address all aspects of the disease.

Izokibep’s design features high potency through tight binding affinity to IL-17A, promoting robust tissue penetration due to its small molecular size—about one-tenth that of a monoclonal antibody. Additionally, it includes an albumin binding domain that extends its half-life. These characteristics are believed to offer clinically meaningful and differentiated benefits, potentially resolving key disease manifestations. Izokibep is currently in late-stage trials not only for PsA but also for moderate-to-severe hidradenitis suppurativa (HS) and uveitis, with plans to begin a Phase 3 program for axial spondyloarthritis (AxSpA).

ACELYRIN, based in the Los Angeles area with additional operations in the San Francisco Bay area, is a late-stage clinical biopharmaceutical company dedicated to bringing transformative medicines to patients. The company’s mission is to identify, acquire, and accelerate the development and commercialization of life-changing treatments. In addition to izokibep, ACELYRIN is advancing another promising therapeutic, lonigutamab. This monoclonal antibody targets IGF-1R and is being developed in Phase 2b/3 trials for thyroid eye disease.

The upcoming presentation of izokibep’s trial results signifies a significant step in the development of new, effective treatments for psoriatic arthritis and other inflammatory diseases. By showcasing the promising data at a prestigious international congress, ACELYRIN aims to highlight izokibep’s potential to improve patient outcomes significantly. The company continues to make strides in the biopharmaceutical field, focusing on delivering innovative therapies that address unmet medical needs.